Cargando…
A phase I/II study of gemcitabine and fractionated cisplatin in an outpatient setting using a 21-day schedule in patients with advanced and metastatic bladder cancer
A randomised phase III trial of MVAC (methotrexate, vincristine, doxorubicin, cisplatin) vs gemcitabine and cisplatin (GC) (G 1000 mg m(−2) days 1, 8, and 15 plus C 70 mg m(−2) day 2, q 4 wks) indicated GC had similar efficacy and lower toxicity (JCO 2000). Significant haematologic toxicities in the...
Autores principales: | Hussain, S A, Stocken, D D, Riley, P, Palmer, D H, Peake, D R, Geh, J I, Spooner, D, James, N D |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2004
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409873/ https://www.ncbi.nlm.nih.gov/pubmed/15292922 http://dx.doi.org/10.1038/sj.bjc.6602112 |
Ejemplares similares
-
Long-term results of a phase II study of synchronous chemoradiotherapy in advanced muscle invasive bladder cancer
por: Hussain, S A, et al.
Publicado: (2004) -
Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma
por: Corrie, P. G., et al.
Publicado: (2020) -
A Phase II study of gemcitabine and cisplatin in chemotherapy-naive, unresectable gall bladder cancer
por: Doval, D C, et al.
Publicado: (2004) -
Successful treatment of metastatic bladder cancer by gemcitabine‐cisplatin re‐challenge after pembrolizumab
por: Arai, Takayuki, et al.
Publicado: (2021) -
Phase II study of gemcitabine and cisplatin in locally advanced/metastatic oesophageal cancer
por: Millar, J, et al.
Publicado: (2005)